Journal of Jilin University(Medicine Edition) ›› 2019, Vol. 45 ›› Issue (01): 105-110.doi: 10.13481/j.1671-587x.20190120

Previous Articles    

Dynamic variety of serum Nesfatin-1 and its clinical values in evaluation on illness condition and short-term prognosis in patients with epileptic seizure

CHEN Min, XIE Ming, WAN Juan   

  1. Department of Neurology, First Affiliated Hospital, University of South China, Hengyang 421001, China
  • Received:2018-01-23 Published:2019-01-28
  • Contact: 湖南省卫计委科研基金资助课题(B2015-55) E-mail:xieming1212@sohu.com

Abstract: Objective: To analyze the dynamic variety of serum Nesfatin-1 in the patients with status epilepticus(SE), and to explore the clinical values of the serum Nesfatin-1 in evaluation on the illness condition and short-term prognosis in the patients with epileptic seizure.Methods: A total of 43 patients diagnosed as primary epilepsy were collected as the subjects and received the regular clinical therapy. The serum levels of Nesfatin-1 of the patients were detected before treatment and at the end of the 1st week after treatment, the end of the 2nd week therapy after treatment and the end of the 1st month after treatment, respectively. Liverpool Seizure Severity Scale 2.0 (LSSS2.0) was used to evaluate in the patients. The correlations of the serum levels of Nesfatin-1 of the patients at each time point with the scores of LSSS were analyzed.After one year of follow-up, all patients were divided into two groups according to the prognosis, which were survival group (31 cases) and death group (12 cases). The risk factors of one-year prognosis were analyzed by multivariate Logistic regression analysis. The sensitivity and specificity of the serum values of Nesfatin-1 to the one-year prognosis were analyzed by receiver operating characteristic (ROC) curve.Results: Compared with before treatment, the LSSS scores and the serum Nesfatin-1 levels of the patients in two groups were decreased with the increasing of treatment time (P<0.05). The LSSS scores and the serum levels of Nesfatin-1 of the patients were not different between two groups before treatment (P>0.05).The LSSS scores and the serum levels of Nesfatin-1 of the SE patients in survival group were lower than these in death group from the end of the 1st week after treatment to the end of the 1st month after treatment (P<0.05 or P<0.01). The positive correlations of the serum levels of Nesfatin-1 and the LSSS scores of the patients at each time point were confirmed (r=0.617-0.726,P<0.05).The serum high level of Nesfatin-1 was the risk factor of the one-year prognosis analyzed by multivariate Logistic regression analysis. The ROC curve identified the cutoff level of serum Nesfatin-1 (2.7μg·L-1) to the one-year prognosis with the sensitivity of 88.5% and specificity of 79.6%.Conclusion: The dynamic variety of serum Nesfatin-1 can reflect the condition of illness, and the serum level of Nesfatin-1 is decreased gradually with the prolongation of time, and has application value in predicting the prognosis of the patients with epileptic seizure.

Key words: Nesfatin-1, epileptic seizure, illness condition, prognosis

CLC Number: 

  • R742.1